approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-by-us-fda

Nucala is the only approved biologic studied in a wide COPD population with an eosinophilic phenotype characterised by blood eosinophil count (BEC) starting at 150 cells/μL
- Approval based on the positive MATINEE and METREX phase III trials
- MATINEE data included reduction of…

This story appeared on gsk.com, 2025-05-23 01:13:57.015000.
The Entire Business World on a Single Page. Free to Use →